Allergan Wins First Approval for Short-Acting Neurotoxin in Canada
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
The FDA has cleared Merz Aesthetics’ Ultherapy PRIME to improve the appearance of skin laxity on the knees, expanding the device’s body indications.